Neuroblastoma Team Bibliography

The bibliography below lists the neuroblastoma team’s articles related to Memorial Sloan Kettering protocols. This is not “required reading” and is only meant for reference.

Reviews: Principles and practice of immunotherapy:

Cheung NKV, Kushner BH, Kramer K: Monoclonal antibody-based therapy of neuroblastoma. Hematology Oncology Clinics of North America. 15 (5): 853-866, 2001 2001.

Cheung NKV, Yu A: Immunotherapy of Neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (editors): Neuroblastoma. Amsterdam, Elsevier Science B.V., 2000, pp 541-546

Cheung NKV and Clio Rooney. Principles of Immune and Celllular Therapy. In: Pizzo, PA, Poplack, DG. eds. Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia: J.B. Lippincott Company, 2002 p.381-408.

Larson SM, Divgi C, Sgouros G, Cheung NKV, Scheinberg DA: Monoclonal Antibodies: Basic Priniciples - Radioisotope Conjugates. In: DeVita VT, Hellman S, Rosenberg SA (editors.): Biologic Therapy of Cancer - Principles and Practice. Philadelphia, J.B. Lippincott Company, 2000, pp 396-412

Reviews of neuroblastoma:

Cheung NKC, Kushner BH: Neuroblastoma. In: Finberg L (ed). Saunders Manual of Pediatric Practice. Philadelphia, WB Saunders Co., 1998, pp 466-468

Cheung NKV, Kushner BH, LaQuaglia M, Lindsley K: Treatment of Advanced Stage Neuroblastoma. In: Reghavan D, Scher HI, Leibel SA, Lange P (editors): Principles and Practice of Genitourinary Oncology. Philadelphia, J.B. Lippincott Company, 1997, pp 1101-1111

Kushner BH, LaQuaglia M, Cheung NKV: Therapeutic Approach to Low-Risk and Intermediate-Risk neuroblastoma. In: Reghavan D, Scher HI, Leibel SA, Lange P (editors): Principles and Practice of Genitourinary Oncology. Philadelphia, J.B. Lippincott Company, 1997, pp 1085-1094

Bonilla MA, Cheung NKV: Clinical progress in neuroblastoma. Cancer Investigation 12: 644-653, 1994.

Kushner BH, Cheung NKV: Neuroblastoma: an overview. Hematology/Oncology Annals 1:189-201, 1993.

Kushner BH, Cheung NKV: Neuroblastoma. In: Horwich A (ed): Combined Chemotherapy and Radiotherapy in Clinical Oncology. Kent, England, Edward Arnold, 1992, pp 223-238

3F8 treatments in patients:

Cheung NKV, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA: Ganglioside GD2 specific monoclonal antibody 3F8 - a phase I study in patients with neuroblastoma and malignant melanoma. Journal of Clinical Oncology 5:1430-1440, 1987.

Cheung NKV, Kushner BH, Yeh SJ, Larson SM: 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study. International Journal of Oncology 12:1299-1306, 1998.

Cheung NKV, Kushner BH, Cheung IY, Canete A, Gerald W, Liu C, Finn R, Yeh SJ, Larson, SM: Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. Journal of Clinical Oncology 16:3053-60, 1998.

Cheung NKV, Kushner BH, LaQuaglia M, Kramer K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, Larson SM, Wuest D, Byrnes M, Dantis E, Mora J, Cheung IY, Rosenfield N, Abramson S, O’Reilly RJ: N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology 36:227-230, 2001.

Kushner BH, Kramer K, Cheung NKV: Phase II trial of 3F8 monoclonal antibody and granulocyte-macrophage colony-stimulating factor for neuroblastoma. Journal of Clinical Oncology 19: 4189-4194, 2001.

Use of radiolabeled 3F8 for imaging neuroblastoma in patients:

Miraldi FD, Nelson AD, Kraly C, Ellery S, Landmeier B, Coccia PF, Strandjord SE, Cheung NKV: Diagnostic imaging of human neuroblastoma with radiolabeled antibody. Radiology 161:413-418, 1986.

Fletcher BD, Miraldi FD, Cheung NKV: Comparison of radiolabeled monoclonal antibody and magnetic resonance imaging in the detection of metastatic neuroblastoma in bone marrow: Preliminary results. Pediatric Radiology 20:72-75, 1989.

Yeh SD, Larson SM, Burch L, Kushner BH, LaQuaglia M, Finn R, Cheung NKV: Radioimmunodetection of neuroblastoma with 131I-3F8: Correlation with biopsy, 131-I-metaiodo-benzylguanidine (MIBG) and standard diagnostic modalities. Journal of Nuclear Medicine 32:769-776, 1991.

Larson SM, Pentlow KS, Volkow ND, Wolf AP, Finn RD, Lambrecht RM, Graham MC, DiResta G, Bendriem B, Daghighian F, Yeh SDJ, Wang GJ, Cheung NKV: PET scanning of iodine-124-3F8 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. Journal of Nuclear Medicine 33:2020-2023, 1992.

Dosimetry of antibody 3F8 delivery to tumor in patients:

Pentlow KS, Graham MC, Lambrecht RM, Cheung NKV, Larson SM: Quantitative imaging of I-124 positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Medical Physics 18: 357-366, 1991.

Daghighian F, Pentlow KS, Larson SM, Graham MC, DiResta GR, Yeh SDJ, Macapinlac H, Finn RD, Arbit E, Cheung NKV: Development of a method to measure kinetics of radiolabeled monoclonal antibody in human tumors with applications to microdosimetry: Positron emission tomography studies of iodine-124 labeled 3F8 monoclonal antibody in glioma. European Journal of Nuclear Medicine 20:402-409, 1993.

Monoclonal antibody 3F8 and tumor/normal tissue reactivity:

Cheung NKV, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Research 45:2642-2649, 1985.

Saito M, Yu RK, Cheung NKV: Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Comm 127:1-4, 1985.

Ye JN, Cheung NKV. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies. International Journal of Cancer 50:197-201, 1992.

Lammie GA, Cheung NKV, Gerald W, Rosenblum M, Cordon-Cardo C: Ganglioside GD2 expression in the human nervous system and in neuroblastomas - An immunohistochemical study. International Journal of Oncology 1993 3:909-915, 1993.

Kramer K, Gerald W, Kushner BH, Larson SM, Hameed M, Cheung NKV: Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Clinical Cancer Research, 4:2135-9, 1998.

Mechanisms of 3F8 mediated tumor killing:


Cheung NKV, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME: Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. Journal of Clinical Investigation 81:1122-1128, 1988.

Juhl H, Petrella EC, Cheung NKV, Bredehorst R, Vogel CW: Complement killing of human neuroblastoma cells: a cytotoxic antibody and its F(ab’)2-cobra venom factor conjugate are equally cytotoxic. Mol Immunol 27:957-964, 1990.

Chen S, Caragine T, Cheung NKV, Tomlinson S: Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. American Journal of Pathology 156:1085-1091, 2000.

Chen S, Caragine T, Cheung NKV, Tomlinson S: Expression of CD59 enhances tumor growth in a rat model of human neuroblastoma. Cancer Research 60: 3013-3018, 2000.

Juhl H, Petrella EC, Cheung NKV, Bredehorst R, Vogel CW: Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiol 197:444-459, 1997.

ADCC (antibody-dependent cellular cytotoxicity):

Munn DH, Cheung NKV: Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma. Cancer Research 47:6600-6605, 1987.

Kushner BH, Cheung NKV: GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936-1941, 1989.

Munn DH, Cheung NKV: Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. Journal of Experimental Medicine 170:511-526, 1989.

Munn DH, Garnick MB, Cheung N-KV: Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and anti-tumor cytotoxicity in nonhuman primates. Blood 75:2042-2048, 1990.

Munn DH, Cheung NKV: Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. Journal of Experimental Medicine 172:231-237, 1990.

Kushner BH, Cheung NKV: Clinically effective monoclonal antibody 3F8 mediates non-oxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Cancer Research 51:4865-4870, 1991.

Munn DH, McBride M, Cheung NKV: The role of the low affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Research 51:1117-1123, 1991.

Kushner BH, Cheung NKV: Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphotidylinositol (PI)-linked FcRIII for monoclonal antibody (MoAb)-mediated neutrophil (PMN) anti-human tumor cytotoxicity. Blood 79:1484-1490, 1992.

Cytotoxic T-lymphocytes specific for ganglioside GD2:

Zhao XJ, Cheung NKV: GD2 oligosaccharide: target for cytotoxic T lymphocytes. Journal of Experimental Medicine 182: 67-74, 1995.

3F8 anti-idiotypic antibodies:

Cheung NKV, Canete A, Cheung I, Ye JN, Liu Chongyuan: Disialoganglioside GD2 anti- idiotypic monoclonal antibodies. International Journal of Cancer 54:499-505, 1993.

Cheung NKV, Cheung IY, Canete A, Yeh SJ, Kushner BH, Bonilla MA, Heller G, Larson, SM: Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Research. 54:2228-2233, 1994.

Cheung NKV, Guo HF, Heller G, Cheung IY: Induction of Ab3 and Ab3’ antibody was associated with long-term survival following anti-GD2 antibody therapy of stage 4 neuroblastoma. Clinical Cancer Research 6:2653-2660, 2000.

Detection of bone marrow disease:

Use of anti-GD2 3F8 antibody to detect microscopic marrow disease:

Cheung NKV, Von Hoff DD, Strandjord S, Coccia PF: Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. Journal of Clinical Oncology 4:363-369, 1986.

Frantz CN, Ryan DH, Cheung NKV: Sensitive detection of rare metastatic human neuroblastoma (NB) cells in bone marrow (BM) by two-color immunofluorescence and cell sorting. In: Evans AE, D’Angio GJ, Knudson AG, Seeger RC, (editors.): Prog Clin Biol Res, Vol 271: Advances in Neuroblastoma Research. New York, Alan Liss, 1988, pp 249-262

Cheung NKV, Heller G, Kushner BH, Liu C, Cheung IY: Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? Journal of Clinical Oncology 15:2807-2817, 1997.

Use of GD2-synthase quantitative RT-PCR to detect microscopic marrow disease:

Cheung IY, Cheung NKV: Quantitation of marrow disease in neuroblastoma by real-time RT-PCR. Clinical Cancer Research 7:1698-1705, 2001.

Lo Piccolo MS, Cheung NKV, Cheung IY. GD2 Synthase: a new molecular marker for detecting neuroblastoma. Cancer 92:924-31, 2001.

Cheung IY, Lo Piccolo SM, Collins N, Kushner BK, Cheung NKV. Quantitation of GD2 synthase mRNA by real-time reverse transcription-PCR: Utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cancer, 2002 (in press).

Use of GAGE RT-PCR to detect microscopic marrow disease:

Cheung IY, Cheung NKV: Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clinical Cancer Research 3:821-826, 1997.

Cheung IY, Barber D, Cheung NKV: Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and RT-PCR of multiple molecular markers. Clinical Cancer Research 4:2801-2805, 1998.

Cheung IY, Cheung NKV: Detection of microscopic disease: comparing histology, immunocytology (IC), and RT-PCR of tyrosine hydroxylase (TH), GAGE and MAGE. Medical and Pediatric Oncology 36: 210-212, 2001.

Cheung IY, Chi S, Cheung NKV: Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. Medical and Pediatric Oncology 35:632-635, 2000.

Cheung NKV, Norris M: Detection of Microscopic Residual Tumors in Bone Marrow. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (editors): Neuroblastoma. Amsterdam, Elsevier Science B.V., 2000, pp 333-340

3F8 imaging and treatment of GD2-positive tumors in mouse models:

Cheung NKV, Neely JE, Landmeier B, Nelson D, Miraldi F: Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma. Journal of Nuclear Medicine 28:1577-1583, 1987.

Cheung NKV, Landmeier B, Neely J, Nelson D, Abramowsky C, Ellery S, Adams R, Miraldi FD: Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2 specific monoclonal antibody against human neuroblastoma xenografted in nude mice. Jounral of the National Cancer Institute 77:739-745, 1986.

Ugur O, Scott AM, Kostakoglu L, Hui TE, Masterson ME, Febo R, Sgouros G, Rosa E, Mehta BM, Fisher DR, Cheung NKV, Larson SM: Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model. Nuclear Medicine and Biology 22:87-93, 1995.

Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung NKV, Larson SM: Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross organ beta doses. Nuclear Medicine and Biology 23: 1-8, 1996.

Zhang H, Zhang S, Cheung NKV, Ragupathi G, Livingston PO: Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Research, 58: 2844-2849, 1998.

Fonti R, Cheung NKV, Bridger GJ, Guo HF, Abrams MJ, Larson SM: 99mTc-monoclonal antibody radiolabeled via hydrazio nicotinamide derivative for imaging ganglioside GD2-positive tumors. Nuclear Medicine and Biology 26:681-686, 1999.

Molecular genetics of neuroblastoma:

Mora, J, Cheung NKV, Kushner BH, LaQuaglia, MP, Kramer K, Fazzari M, Heller G, Chen L, Gerald WL: Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. Journal of Molecular Diagnostics 2:1-9, 2000.

Mora J, Gerald W, Chen L, Qin J, Cheung NKV: Survival analysis of clinical, pathologic and genetic features in neuroblastoma presenting as local-regional diseases. Cancer 91:435-442, 2001.

Mora J, Akram M, Cheung NKV, Chen L, Gerald WL: Microdissected schwannian and neuroblastic cells in stage 4 neuroblastomas have the same genetic alterations. Medical and Pediatric Oncology 35:534-537, 2000.

Mora J, Cheung NK, Juan G, Cheung I, Illei P, Chi S, Ladanyi M, Cordon-Cardo C, Gerald WL. Neuroblastoma originates from a stem cell capable of developing along multiple lineages. Cancer Research 61:6892-6898, 2001.

Mora J, Cheung NKV, Chen L, Qin J, William G: Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clinical Cancer Research 7:1358-1361, 2001.

Mora J, Gerald W, Quin J, Cheung NKV. Evolving significance of prognostic markers associated with treatment improvement in stage 4 neuroblastoma. Cancer, 2002 (in press)

Mora J, Cheung NKV, Oplanich S, Chen L, Gerald WL. Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Research 62:1761-1767, 2002.

Mora J, Cheung NKV, Gerald WL. Clonal heterogeneity and evolution in neuroblastoma. British Journal of Cancer 85:182-9, 2001.

Mora J, Gerald WL, Qin J, Cheung NKV. Molecular genetics of neuroblastoma and the implications for clinical management. A review of the MSKCC experience. Oncology 6:263-8, 2001.

Prognostic factors in neuroblastoma:

Kramer K, Gerald W, LeSauteur L, Saragovi HU, Cheung NKV: Prognostic value of TrkA protein detection by monoclonal antibody 5C3 in neuroblastoma. Clinical Cancer Research 2: 1361-1367, 1996.

Kramer K, Gerald W, LeSauteur L, Saragovi HU, Cheung NKV: Monoclonal antibody to human TrkA: diagnostic and therapeutic potential in neuroblastoma. European Journal of Cancer 33: 2090-2091, 1997.

Kramer K, Cheung NKV, Gerald WL, LaQuaglia M, Kushner BH, LeClerc JM, LeSauteur L, Saragovi HU: Correlation of MYCN amplification, TrkA and CD44 expression with clinical stage in 250 patients with neuroblastoma. European Journal of Cancer 33:2098-2100, 1997.

Chemotherapy in the treatment of neuroblastoma:

Cheung NKV, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neurolblastoma. Journal of Clinical Oncology 9:1050-1058, 1991.

Kushner BH, O’Reilly RJ, LaQuaglia M, Cheung NKV: High dosing and dose-rate using cyclophosphamide in ablation of neuroblastoma. Cancer 66:1095-1100, 1990

Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh SDJ, Eddy J, Gerald WL, Heller G, Cheung NKV: Highly effective induction therapy for stage 4 neuroblastoma in children over one year of age. Journal of Clinical Oncology 12:2607-2613, 1994.

Kushner BH, Kramer K, Cheung N-KV: Oral etoposide for refractory and relapsed neuroblastoma. J Clinical Oncology 17:3221-3225, 1999.

Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NKV: Topotecan and high-dose cyclophosphamide: salvage therapy for pediatric tumors. Medical and Pediatric Oncology 35:468-474, 2000.

Kushner BH, Heller G, Kramer K, Cheung NKV: Granulocyte colony-stimulating factor (G-CSF) and multiple cycles of alkylator-based combination chemotherapy in children with neuroblastoma. Cancer 89:2122-2130, 2000.

Bone marrow purging with 3F8 and 4HC:

Saarinen UM, Coccia PF, Gerson SL, Pelley R, Cheung NKV: Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Research 45:5969-5975, 1985.

Stein J, Strandjord S, Saarinen UM, Warkentin PI, Gerson SL, Lazarus HM, Von Hoff DD, Coccia PF, Cheung NKV: In vitro treatment of autologous bone marrow from neuroblastoma patients with anti-GD2 monoclonal antibody and human complement: a pilot study. In: Evans AE, D’Angio GJ, Knudson AG, Seeger RC (editors): Prog Clin Biol Res, Vol 271: Advances in Neuroblastoma Research. New York, Alan Liss, 1988, pp 237-248

Gulati SC, Kwon JH, Kushner B, Cheung NKV, Atzpodiem J, Shum K, Clarkson BD: In vitro chemopurification of neuroblastoma cells: comparison of 6-hydroxydopamine and ascorbic acid with 4-hydroperoxycyclophosphamide. Cancer Investigation 7:417-422, 1989.

Bone marrow transplantation at MSKCC:

Kushner BH, O’Reilly RJ, Mandell LR, Gulati SC, LaQuaglia M, Cheung NKV: Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. Journal of Clinical Oncology 9:274-279, 1991.

Kushner BH, Gulati SC, O’Reilly RJ, Cheung NKV: Autografting with bone marrow exposed to repeated courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophoshamide in vitro. Medical and Pediatric Oncology 18:454-458, 1990.

Kushner BH, Gulati SC, Kwon JH, O’Reilly RJ, Exelby PR, Cheung NKV. High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma: long term survival results of 28 patients. Cancer 9:274-279, 1991.

Kushner BH, Cheung N-KV, Kramer K, Dunkel IJ, Calleja E, Boulad F: Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplantation 28:551-556, 2001.

Surgical resection of neuroblastoma at MSKCC:

LaQuaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsley K, Cheung NKV. Stage 4 neuroblastoma diagnosed at more than one year of age: gross total resection and clinical outcome. Jounral of Pediatric Surgery 29:1162-1164, 1994.

Medary I, Aronson D, Cheung NKV, Ghavimi F, Gerald W, LaQuaglia MP: Kinetics of primary tumor regression with chemotherapy: implications for the timing of surgery. Annals of Surgical Oncology 3:521-525, 1996.

Treatment of local-regional/4s neuroblastoma:

Kushner BH, Cheung NKV, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla MA, Ladanyi M, Gerald WL: INSS stage 1 neuroblastoma: a prospective study and literature review. Journal of Clinical Oncology 14: 2174-2180, 1996.

Kushner BH, Cheung NKV, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla MA, Gerald WL, Ladanyi M, Gilbert F, Rosenfield NS, Yeh DJ: Survival from locally invasive or metastatic neuroblastoma without cytotoxic therapy. Journal of Clinical Oncology 14:373-381, 1996.

Cheung NKV, Kushner BH, LaQuaglia MP, Kramer K, Ambros P, Ambros I, Ladanyi M, Eddy J, Bonilla MA, Gerald W: Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biologic markers. European Journal of Cancer 33:2117-2121, 1997.

Leukemia after dose-intensive therapy:

Kushner BH, Cheung NKV, Kramer K, Heller G, Jhanwar SC: Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan Kettering experience and a literature review. Journal of Clinical Oncology 16:3880-3889, 1998.

Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NKV, Lovett BD, Nowell PC, Blair IA, Rebbeck TR: Association of CYP3A4 with treatment-related leukemia. Proceedings of the National Academy of Sciences (USA) 95:13176-13181, 1998.

Megonigal MD, Cheung NKV, Rappaport EF, Nowell PC, Wilson RB, Jones DH, Addya K, Leonard DGB, Kushner BH, Williams TM, LangeBJ, Felix CA: Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors Proceedings of the National Academy of Sciences (USA) 97:2814-9, 2000.

CNS (central nervous system) and leptomeningeal metastasis in neuroblastoma:

Kramer K, Kushner B, Heller G, Cheung NKV: Neuroblastoma metastatic to the central nervous system: the Memorial Sloan Kettering Cancer Center experience and a literature review. Cancer 91:1510-1519, 2001.

Kramer K, Cheung NKV, DiResta G, Humm J, Arbit E, Larson SM, Finn R, Rosenblum M, Nguyen H, Gonzalez G, Liu CJ, Yang YF, Mendelsohn ME, Gillio AP: Pharmacokinetics and acute toxicology of intraventricular 131I-monoclonal antibody targeting disialoganglioside in non-human primates. Journal of Neurooncology 35:101-111, 1997.

Kramer K, Cheung NKV, Humm JL, Dantis E, Finn R, Yeh SJ, Antunes NL, Dunkel IJ, Souwedaine M, Larson SM: Targeted radioimmunotherapy for leptomeningeal cancer using 131-I-3F8. Medical and Pediatric Oncology 35:716-718, 2000.

Radiation therapy for neuroblastoma:

Wolden SL, Gollamudi SV, Kushner BH, LaQuaglia M, Kramer K, Rosenfield N, Abramson S, Cheung N-KV: Local control with multimodality therapy for stage 4 neuroblastoma. International Journal of Radiation Oncology Biology Physics 46:969-974, 2000.

Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G, Cheung NKV: Hyperfractionated low-dose (21 Gy) radiotherapy for high-risk neuroblastoma following intensive chemotherapy and surgery. Journal of Clinical Oncology 2001 (in press).

Arsenic Trioxide:

Soignet S, Bienvenu B, Cheung N, Vongphrachanh P, Calleja E, Pezzulli S, Ellison R, Spriggs D, Warrell RP. Clinical and pharmacologic study of arenic trioxide (As2O3) in patients with solid tumors. 36th Annual Meeting of ASCO. 19:201a, 2000.

PET imaging in patients with neuroblastoma:

Kushner BH, Yeung H, Kramer K, Larson S, Cheung NKV: Adequacy of positron emission tomography as sole imaging modality in routine followup of patients with high risk neuroblastoma. Journal of Clinical Oncology 2001 (in press)